Market accessOfficial

Czech regulator flags supply interruption for Invega 9 mg paliperidone prolonged-release tablets

🇨🇿 SÚKL · Wed 21 Oct 2026

SÚKL has published a notice from Janssen-Cilag on the interruption of supplies of Invega 9 mg tablets in the 49-tablet pack, giving no cause or restart date.

The Czech State Institute for Drug Control (SÚKL) published a notice on 21 October 2026 about an interruption in supplies of Invega 9 mg prolonged-release tablets. The notice was issued by its medicines availability department.

The affected product is the 49-tablet pack of Invega 9 mg, registered under SÚKL code 0028987. The active substance is paliperidone, supplied as prolonged-release tablets.

According to the notice, the marketing company Janssen-Cilag s.r.o. is informing the market in cooperation with SÚKL. The announcement is also available as a PDF attachment, which was not part of the text reviewed for this article.

The web notice does not state the reason for the interruption or when supplies are expected to resume. It also does not say whether other strengths or pack sizes of Invega are affected.

What it means for your team

  • Prescribers and pharmacies in the Czech Republic should check stock of SÚKL code 0028987 and plan for patients who may be affected.
  • Teams tracking Czech availability should consult the attached PDF notice for any further detail, as the web text gives no cause or timeline.
  • Market-access and supply-chain teams should monitor SÚKL for updates on resumption, since none has been announced.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →